Growth Hormone Treatment in Adult Patients With Chronic Kidney Disease

The Effect of Norditropin® on Nutritional Status in Adult Patients in Chronic Haemodialysis

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00184652

Enrollment

140

Registered

2005-09-16

Start date

2003-04-30

Completion date

2005-09-30

Last updated

2017-01-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Kidney Disease, End-Stage Renal Disease

Brief summary

This trial is conducted in Asia, Europe, and Middle East. Adult patients with chronic kidney disease are treated with growth hormone to assess effect on nutritional status.

Interventions

DRUGsomatropin

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

18 Years to 99 Years

Healthy volunteers

Inclusion criteria

* ESRD patients

Exclusion criteria

* Diabetes Mellitus * Severe and Malignant diseases * Patients in Intensive Care Units

Design outcomes

Primary

Measure	Time frame
Change in surrogate markers of nutrition	After 6 months treatment

Secondary

Measure	Time frame
Quality of Life	—
Other markers of nutrition	—

Countries

Denmark, Germany, Hong Kong, Israel, Poland, Singapore, Sweden, Switzerland, United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026